Summit Therapeutics Says Ivonescimab Meets Primary Endpoint in Phase II Endometrial Cancer Study

By Public Technologies
  • Summit Therapeutics will feature 10 ivonescimab presentations at ESMO 2026, scheduled for October 23-27 in Madrid.
  • Akeso's China-based Phase III HARMONi-GI1 trial showed positive overall survival findings versus durvalumab, both with chemotherapy, in first-line advanced biliary tract cancer.
  • Ivonescimab monotherapy met a Phase II endometrial cancer study's tumor response goal, with manageable safety and no new safety signals.
  • Those results supported expansion of the investigator-sponsored endometrial cancer trial.
  • A separate US Phase II/III biliary tract cancer trial with ECOG-ACRIN expects clinical site activation in the fourth quarter of 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Summit Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261022076516) on October 22, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.